{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T04:18:18Z","timestamp":1769919498484,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T00:00:00Z","timestamp":1593216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T00:00:00Z","timestamp":1593216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Oxaliplatin, one of the key cytotoxic drugs for colorectal cancer, frequently causes peripheral neuropathy which leads to dose modification and decreased patients\u2019 quality of life. However, prophylactic or therapeutic measures have not yet been established. Orally administered amino acids, cystine and theanine, promoted the synthesis of glutathione which was one of the potential candidates for preventing the neuropathy. The aim of this study was to determine whether daily oral administration of cystine and theanine attenuated oxaliplatin-induced peripheral neuropathy (OXLIPN).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Twenty-eight colorectal cancer patients who received infusional 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) therapy were randomly and evenly assigned to the cystine and theanine group and the control group. OXLIPN was assessed up to the sixth course using original 7-item questionnaire as well as Common Terminology Criteria for Adverse Events (CTCAE) grading scale.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Neuropathy scores according to our original questionnaire were significantly smaller in the cystine and theanine group at the fourth (<jats:italic>p<\/jats:italic>\u2009=\u20090.026), fifth (<jats:italic>p<\/jats:italic>\u2009=\u20090.029), and sixth course (<jats:italic>p<\/jats:italic>\u2009=\u20090.038). Furthermore, significant differences were also observed in CTCAE neuropathy grades at the fourth (<jats:italic>p<\/jats:italic>\u2009=\u20090.037) and the sixth course (<jats:italic>p<\/jats:italic>\u2009=\u20090.017). There was one patient in each group who required dose reduction due to OXLIPN. Except for neurotoxicity, no significant differences were noted in the incidence of adverse events, and the total amount of administered oxaliplatin.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The results demonstrated the daily oral administration of cystine and theanine attenuated OXLIPN.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s10147-020-01728-4","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T20:04:16Z","timestamp":1593288256000},"page":"1814-1821","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial"],"prefix":"10.1007","volume":"25","author":[{"given":"Minoru","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Komura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetaka","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Hirashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Otake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaho","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Kakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Oikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2594-1811","authenticated-orcid":false,"given":"Takashi","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,27]]},"reference":[{"key":"1728_CR1","unstructured":"GLOBOCAN database 2018. https:\/\/gco.iarc.fr\/today\/home. Accessed 20 Jan 2020"},{"key":"1728_CR2","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1023\/A:1026520812351","volume":"11","author":"F Maindrault-Goebel","year":"2000","unstructured":"Maindrault-Goebel F, de Gramont A, Louvet C et al (2000) Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Ann Oncol 11:1477\u20131483","journal-title":"Ann Oncol"},{"key":"1728_CR3","first-page":"637","volume":"71","author":"Y Kidani","year":"1980","unstructured":"Kidani Y, Noji M, Tashiro T (1980) Antitumor activity of platinum (II) complexes of 1,2-diamino-cyclohexane isomers. GANN Jpn J Cancer Res 71:637\u2013643","journal-title":"GANN Jpn J Cancer Res"},{"key":"1728_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.critrevonc.2006.01.001","volume":"59","author":"LM Pasetto","year":"2006","unstructured":"Pasetto LM, D'Andrea MR, Rossi E et al (2006) Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol 59:159\u2013168","journal-title":"Crit Rev Oncol Hematol"},{"key":"1728_CR5","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1200\/JCO.2014.58.8533","volume":"33","author":"DR Pachman","year":"2015","unstructured":"Pachman DR, Qin R, Seisler DK et al (2015) Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (alliance). J Clin Oncol 33:3416\u20133422","journal-title":"J Clin Oncol"},{"key":"1728_CR6","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 T, Boni C, Mounedji-Boudiaf L et al (2004) Multicenter international study of oxaliplatin\/5-fluorouracil\/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343\u20132351","journal-title":"N Engl J Med"},{"key":"1728_CR7","first-page":"4828563","volume":"2019","author":"EG Gebremedhn","year":"2019","unstructured":"Gebremedhn EG, Shortland PJ, Mahns DA (2019) Variability of oxaliplatin-induced neuropathic pain symptoms in each cycle and its implications on the management of colorectal cancer patients: a retrospective study in South Western Sydney Local Health District Hospitals, Sydney. Australia J Oncol 2019:4828563","journal-title":"Australia J Oncol"},{"key":"1728_CR8","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","volume":"32","author":"DL Hershman","year":"2014","unstructured":"Hershman DL, Lacchetti C, Sworkin RH et al (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: american society of clinical oncology clinical practice guideline summary. J Clin Oncol 32:1941\u20131967","journal-title":"J Clin Oncol"},{"key":"1728_CR9","doi-asserted-by":"publisher","first-page":"C1964","DOI":"10.1152\/ajpcell.2001.281.6.C1964","volume":"281","author":"AC Rimaniol","year":"2001","unstructured":"Rimaniol AC, Mialocq P, Clayette P et al (2001) Role of glutamate transporters in the regulation of glutathione levels in human macrophages. Am J Physiol Cell Physiol 281:C1964\u2013C1970","journal-title":"Am J Physiol Cell Physiol"},{"key":"1728_CR10","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/2101358b0","volume":"210","author":"AM Asatoor","year":"1966","unstructured":"Asatoor AM (1966) Tea as a source of urinary ethylamine. Nature 210:1358\u20131360","journal-title":"Nature"},{"key":"1728_CR11","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1200\/JCO.2002.07.061","volume":"20","author":"S Cascinu","year":"2002","unstructured":"Cascinu S, Catalano V, Cordella L et al (2002) Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 20:3478\u20133483","journal-title":"J Clin Oncol"},{"key":"1728_CR12","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/CAD.0b013e32832a2dc1","volume":"20","author":"P Milla","year":"2009","unstructured":"Milla P, Airoldi M, Weber G et al (2009) Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. Anticancer Drugs 20:396\u2013402","journal-title":"Anticancer Drugs"},{"key":"1728_CR13","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s00520-006-0018-9","volume":"14","author":"PC Lin","year":"2006","unstructured":"Lin PC, Lee MY, Wang WS et al (2006) N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. Support Care Cancer 14:484\u2013487","journal-title":"Support Care Cancer"},{"key":"1728_CR14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1634\/theoncologist.12-3-312","volume":"12","author":"WS Wang","year":"2007","unstructured":"Wang WS, Lin JK, Lin TC et al (2007) Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 12:312\u2013319","journal-title":"Oncologist"},{"key":"1728_CR15","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s10147-016-0996-7","volume":"21","author":"T Tsuchiya","year":"2016","unstructured":"Tsuchiya T, Honda H, Oikawa M et al (2016) Oral administration of the amino acids cystine and theanine attenuates the adverse events of S-1 adjuvant chemotherapy in gastrointestinal cancer patients. Int J Clin Oncol 21:1085\u20131090","journal-title":"Int J Clin Oncol"},{"key":"1728_CR16","unstructured":"Common Terminology Criteria for Adverse Events version 4.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed 20 Jan 2020"},{"key":"1728_CR17","unstructured":"ECOG performance status. https:\/\/www.npcrc.org\/files\/news\/ECOG_performance_status.pdf. Accessed 20 Jan 2020"},{"key":"1728_CR18","first-page":"741","volume":"13","author":"EA Calhoun","year":"2003","unstructured":"Calhoun EA, Welshman EE, Chang CH et al (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity (Fact\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13:741\u2013748","journal-title":"Int J Gynecol Cancer"},{"key":"1728_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1046\/j.1525-1438.1996.06050415.x","volume":"6","author":"GML Bogliun","year":"1996","unstructured":"Bogliun GML, Marzola M, Miceli MD et al (1996) Neurotoxicity of cisplatin +\/- reduced glutathione in the first-line treatment of advanced ovarian cancer. Int J Gynecol Cancer 6:415\u2013419","journal-title":"Int J Gynecol Cancer"},{"key":"1728_CR20","first-page":"617","volume":"112","author":"M Schmidinger","year":"2000","unstructured":"Schmidinger M, Budinsky AC, Wenzel C et al (2000) Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer. Wien Klin Wochenschr 112:617\u2013623","journal-title":"Wien Klin Wochenschr"},{"key":"1728_CR21","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/cncr.28654","volume":"120","author":"AD Leal","year":"2014","unstructured":"Leal AD, Qin R, Atherton PJ et al (2014) North Central Cancer Treatment Group\/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel\/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890\u20131897","journal-title":"Cancer"},{"key":"1728_CR22","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3346\/jkms.2005.20.5.721","volume":"20","author":"SY Hong","year":"2005","unstructured":"Hong SY, Gil HW, Yang JO et al (2005) Pharmacokinetics of glutathione and its metabolites in normal subjects. J Korean Med Sci 20:721\u2013726","journal-title":"J Korean Med Sci"},{"key":"1728_CR23","unstructured":"Clinical pharmacology and biopharmaceutics review NDA 21-492 SE8-S008. https:\/\/www.fda.gov\/files\/drugs\/published\/N21492s008-Oxaliplatin-Clinpharm-BPCA.pdf"},{"key":"1728_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1200\/JCO.1995.13.1.26","volume":"13","author":"S Cascinu","year":"1995","unstructured":"Cascinu S, Cordella L, Del Ferro E et al (1995) Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 13:26\u201332","journal-title":"J Clin Oncol"},{"key":"1728_CR25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1023\/A:1008211226339","volume":"8","author":"JF Smyth","year":"1997","unstructured":"Smyth JF, Bowman A, Perren T et al (1997) Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann Oncol 8:569\u2013573","journal-title":"Ann Oncol"},{"key":"1728_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1529-8027.2007.00141.x","volume":"12","author":"G Cavaletti","year":"2007","unstructured":"Cavaletti G, Frigeni B, Lanzani F et al (2007) The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 12:210\u2013215","journal-title":"J Peripher Nerv Syst"},{"key":"1728_CR27","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00520-008-0550-x","volume":"17","author":"K Kuroi","year":"2009","unstructured":"Kuroi K, Shimozuma K, Ohashi Y et al (2009) Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study). Support Care Cancer 17:1071\u20131080","journal-title":"Support Care Cancer"},{"key":"1728_CR28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1023\/A:1008344507482","volume":"9","author":"TJ Postma","year":"1998","unstructured":"Postma TJ, Heimans JJ, Muller MJ et al (1998) Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9:739\u2013744","journal-title":"Ann Oncol"},{"key":"1728_CR29","doi-asserted-by":"publisher","first-page":"E111","DOI":"10.1188\/17.ONF.E111-E123","volume":"44","author":"H Haryani","year":"2017","unstructured":"Haryani H, Fetzer SJ, Wu CL et al (2017) Chemotherapy-induced peripheral neuropathy assessment tools: a systematic review. Oncol Nurs Forum 44:E111\u2013E123","journal-title":"Oncol Nurs Forum"},{"key":"1728_CR30","first-page":"W1","volume":"4","author":"JA Kopec","year":"2006","unstructured":"Kopec JA, Land SR, Cecchini RS et al (2006) Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. J Supp Oncol 4:W1\u2013W8","journal-title":"J Supp Oncol"},{"key":"1728_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.seminoncol.2005.12.010","volume":"33","author":"FH Hausheer","year":"2006","unstructured":"Hausheer FH, Schilsky RL, Bain S et al (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33:15\u201349","journal-title":"Semin Oncol"},{"key":"1728_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K et al (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer. Ann Oncol 26:141\u2013148","journal-title":"Ann Oncol"},{"key":"1728_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-017-1101-6","volume":"23","author":"T Watanabe","year":"2018","unstructured":"Watanabe T, Muro K, Ajioka Y et al (2018) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol 23:1\u201334","journal-title":"Int J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01728-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-020-01728-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01728-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T23:44:50Z","timestamp":1624751090000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-020-01728-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,27]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1728"],"URL":"https:\/\/doi.org\/10.1007\/s10147-020-01728-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,27]]},"assertion":[{"value":"16 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No author has any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}